コンテンツへスキップ
Merck
  • Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.

Nature structural & molecular biology (2020-05-10)
Zhenming Jin, Yao Zhao, Yuan Sun, Bing Zhang, Haofeng Wang, Yan Wu, Yan Zhu, Chen Zhu, Tianyu Hu, Xiaoyu Du, Yinkai Duan, Jing Yu, Xiaobao Yang, Xiuna Yang, Kailin Yang, Xiang Liu, Luke W Guddat, Gengfu Xiao, Leike Zhang, Haitao Yang, Zihe Rao
要旨

The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro). Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 μM) and is a promising lead compound to develop new antiviral treatment for COVID-19.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
カルモフール, ≥98% (HPLC), powder